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Abstract 
Hypoxia-Inducible Factor (HIF)-1 is a transcription factor that plays the key role in response to low oxygen 
concentrations, or hypoxia. Activation of the HIF-1 pathway is not only crucial for normal tissue 
development and function, but also involved in disease progression, such as cancer. Cancer cells 
proliferate rapidly in solid tumors, and thus, solid tumors consume much more oxygen and nutrients than 
normal tissue and generate oxygen tension. It is well established that oxygen tension in solid tumor tissue 
induces the aberrant activation of the HIF-1 pathway, and subsequently promotes angiogenesis and 
tumor progression. Breast cancer is a heterogeneous disease and can be classified into luminal, Her2 
positive, and triple negative (TNBC) subtypes base on ER/PR and Her2 expression in the breast cancer 
tissue. HIF-1 activation is observed in all breast cancer subtypes; interestingly, the HIF-1 pathway is 
hyperactivated in TNBCs compared to other subtypes. The differential activation of the HIF-1 pathway in 
breast cancer subtypes suggests that oxygen-independent pathways may be involved in HIF-1 regulation 
during TNBC progression. However, these pathways have not been well-characterized. We demonstrate 
that collagen proly 4 hydroxylase 1 (P4H1) induces HIF-1α expression at the protein level by modulating 
α-ketoglutarate (α-KG) and succinate levels. These results reveal a novel link between collagen 
hydroxylation and activation of the HIF-1 pathway and unveil a new HIF-1 regulation mechanism in TNBC. 
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Hypoxia-Inducible Factor (HIF)-1 is a transcription fac-
tor that plays the key role in response to low oxygen 
concentrations, or hypoxia. Activation of the HIF-1 
pathway is not only crucial for normal tissue develop-
ment and function, but also involved in disease pro-
gression, such as cancer. Cancer cells proliferate rapid-
ly in solid tumors, and thus, solid tumors consume 
much more oxygen and nutrients than normal tissue 
and generate oxygen tension. It is well established that 
oxygen tension in solid tumor tissue induces the aber-
rant activation of the HIF-1 pathway, and subsequently 
promotes angiogenesis and tumor progression. Breast 
cancer is a heterogeneous disease and can be classified 
into luminal, Her2 positive, and triple negative (TNBC) 
subtypes base on ER/PR and Her2 expression in the 
breast cancer tissue. HIF-1 activation is observed in all 
breast cancer subtypes; interestingly, the HIF-1 path-
way is hyperactivated in TNBCs compared to other 
subtypes. The differential activation of the HIF-1 
pathway in breast cancer subtypes suggests that oxy-
gen-independent pathways may be involved in HIF-1 
regulation during TNBC progression. However, these 
pathways have not been well-characterized. We 
demonstrate that collagen proly 4 hydroxylase 1 
(P4H1) induces HIF-1α expression at the protein level 
by modulating α-ketoglutarate (α-KG) and succinate 
levels. These results reveal a novel link between colla-
gen hydroxylation and activation of the HIF-1 pathway 
and unveil a new HIF-1 regulation mechanism in TNBC. 
 
Prolyl hydroxylation is a very common posttranslational 
protein modification. About 4% amino acid residues in an-
imal proteins are hydroxyproline, and most of hydroxypro-
line is within collagen. Regulation of protein stability and 
folding is the two major functions for prolyl hydroxylation. 
For instance, the hydroxylation on proline 402 (Pro402) 
and 564 (Pro564) induces ubiquitination and degradation 
of HIF-1α, and the hydroxylation is regulated by a family of 
oxygen-dependent dioxygenases (PHD). Proper folding and 
formation of the collagen triple helix requires 4-
hydroxylation of proline on the GPX repeat region, which is 
catalyzed by Collagen P4H (cP4H). 
CP4H is a α2β2 tetrameric α-KG-dependent dioxygen-
ase, and succinate is a product of the hydroxylation reac-
tion. Three α subunits (P4HA) of cP4H have been identified 
in mammalian cells, and they are responsible for both pep-
tide binding and for catalytic activity. P4HA1 is the major 
isoform and contributes the majority of prolyl 4-
hydroxylase activity in most cell types and tissues. Recently, 
studies showed that expression of P4HA1, 2 and 3 is in-
duced during cancer development and progression, and 
that increased P4HA expression correlates with poor prog-
nosis in cancer patient. Importantly, P4HA1 expression in 
cancer cells is required for breast cancer metastasis. How-
ever, we know little about how expression of P4HA1 in 
cancer cells promotes tumor progression.  
Using unbiased gene coexpression analysis, we have 
identified the HIF-1 pathway as a potential downstream 
target of P4HA1. CP4H has three-fold higher affinity to 
α-KG and six-fold higher affinity to oxygen compared to 
PHD, and about 38% of proline in collagen are hydroxylat-
ed. Therefore, increased expression of cP4H may compete 
with PHD to consume a substantial amount of α-KG (Figure 
1). Indeed, we found that cytoplasmic α-KG levels are re-
duced in P4HA1-expressing cells. Rescue experiments fur-
ther confirm the hypothesis that P4HA1 regulates HIF-1α 
stability by modulating α-KG and succinate levels. Regula-
tion of HIF-1α stability with small metabolites has also 
been demonstrated in glioma. Mutation of IDH-1 in glioma 
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induces the HIF-1 pathway by reducing α-KG production. 
Our results suggest that metabolites such as α-KG and suc-
cinate are regulated by cP4H1 in TNBC, which in turn con-
tributes to HIF-1 activation during breast cancer develop-
ment and progression. It has been shown that lysyl oxidase 
(LOX) expression also increases HIF-1α protein levels. Simi-
lar mechanisms may mediate the crosstalk between LOX 
and HIF-1α. In addition, P4HA1 expression may modulate 
activity of other α-KG-dependent enzymes, such as TET 
enzymes and JMJD histone demethylases. 
HIF-1 pathway is hyperactivated in TNBC and is associ-
ated with poor prognosis. We found that expression of the 
HIF-1 gene signature correlates with P4AH1 levels in breast 
cancer tissue samples. Tissue microarray data showed that 
P4HA1 protein expression is significantly upregulated in 
TNBC compared to ER positive breast cancer. These results 
indicate that activation of the HIF-1 pathway in TNBC is at 
least partially regulated by the P4HA1. However, other 
mechanisms may also contribute to the HIF-1 activation in 
TNBC. For instance, XBP1 interacts with HIF-1α and en-
hances its transcription factor activity and subsequently 
drives TNBC tumorigenicity. In addition, SHARP1 suppress-
es breast cancer metastasis by promoting proteasomal 
degradation of HIFs.    
Activation of the HIF-1 pathway is crucial for the sur-
vival and self-renewal of stem cells. Cancer stem cells are 
the driver of cancer progression and chemoresistance. 
Interestingly, P4HA1 expression is upregulated in cancer 
stem cell enriched cell population. We further demonstrat-
ed that P4HA1 regulates cancer cell stemness through the 
HIF-1 pathway. Importantly, silence or inhibition of P4HA1 
activity sensitizes TNBC to chemotherapeutic agents in 
vitro and in vivo. Moreover, high levels of P4HA1 are asso-
ciated with chemoresistance in TNBC patients. These re-
sults indicate that targeting P4HA1 is a promising strategy 
to inhibit cancer stem cells and overcome chemoresistance 
in TNBC.   
In summary, our findings fill a critical gap in our 
knowledge about the regulation of the HIF-1 pathway and 
tumor-initiating cells during breast cancer progression. 
Given that activation of HIF-1 and expression of P4HA1 are 
particularly robust in TNBC, inhibition of P4HA1 is a prom-
ising strategy for blocking TNBC progression. Therefore, it 
is crucial to identify specific P4HA1 inhibitor in the future. 
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FIGURE 1: A scheme showing the molecular mechanism by which cP4H1 enhances HIF-1stability and cancer cell stemness in TNBC.  
